We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

93 hedge funds and large institutions have $244M invested in BioSpecifics Technologies Corp. in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

29% more capital invested

Capital invested by funds: $189M → $244M (+$54.3M)

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

16% more funds holding

Funds holding: 8093 (+13)

Holders
93
Holders Change
+13
Holders Change %
+16.25%
% of All Funds
2.13%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
17
Increased
34
Reduced
28
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
California State Teachers Retirement System (CalSTRS)
51
California State Teachers Retirement System (CalSTRS)
California
$513K +$2.96K +58 +0.7%
SAM
52
Shell Asset Management
Netherlands
$512K +$447K +8,761 New
Squarepoint
53
Squarepoint
New York
$454K +$396K +7,758 New
GCP
54
GSA Capital Partners
United Kingdom
$427K -$112K -2,200 -23%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$386K
SGAM
56
Smith Group Asset Management
Texas
$359K
Bank of America
57
Bank of America
North Carolina
$347K +$94.4K +1,850 +45%
Citadel Advisors
58
Citadel Advisors
Florida
$340K -$3.47K -68 -1%
GC
59
Globeflex Capital
California
$339K +$35.7K +700 +14%
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$324K +$6.07K +119 +2%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$295K -$15.3K -300 -6%
Los Angeles Capital Management
62
Los Angeles Capital Management
California
$284K
AllianceBernstein
63
AllianceBernstein
Tennessee
$281K +$245K +4,800 New
State of Wisconsin Investment Board
64
State of Wisconsin Investment Board
Wisconsin
$234K +$204K +4,000 New
Janus Henderson Group
65
Janus Henderson Group
United Kingdom
$225K +$196K +3,846 New
AIG
66
American International Group
New York
$223K +$5.61K +110 +3%
ZCM
67
Zebra Capital Management
Connecticut
$212K +$185K +3,619 New
UBS Group
68
UBS Group
Switzerland
$192K +$32.3K +633 +24%
MIM
69
MetLife Investment Management
New Jersey
$178K +$155K +3,035 New
FQ
70
First Quadrant
California
$144K
MAM
71
Meeder Asset Management
Ohio
$137K +$53.9K +1,056 +82%
AAMU
72
Amundi Asset Management US
Massachusetts
$135K +$117K +2,300 New
US Bancorp
73
US Bancorp
Minnesota
$131K -$12.8K -250 -10%
Barclays
74
Barclays
United Kingdom
$126K +$88.9K +1,742 +421%
STA
75
Summit Trail Advisors
New York
$125K +$109K +2,134 New

BSTC Hedge Fund Activity: Q3 2018 in Review

93 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2018, worth a combined $244M — up 29% from $189M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BSTC positions and 4 closed out — a net gain of 13 holders — while 34 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $4.22M. The largest seller was Stonepine Capital Management, cutting an estimated $8.98M.

  • 93 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2018, up from 80 in Q2 2018.
  • Funds reported $244M of BioSpecifics Technologies Corp. stock for Q3 2018, up 29% quarter-over-quarter.
  • 17 funds opened new BioSpecifics Technologies Corp. positions in Q3 2018 and 4 closed out, a net change of +13 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2018 was BlackRock, an estimated $4.22M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2018 was Stonepine Capital Management, an estimated $8.98M sold.

Based on aggregated 13F filings for Q3 2018.